Optimal timing of clopidogrel discontinuation in Japanese patients: platelet aggregation test using the VerifyNow® system

被引：5

作者：

Takiuchi H. ^{[1
]}

Tanemoto K. ^{[1
]}

机构：

[1] Department of Cardiovascular Surgery, Kawasaki Medical School, 577 Matsushima, Kurashiki, 701-0192, Okayama

来源：

General Thoracic and Cardiovascular Surgery | 2015年 / 63卷 / 11期

基金：

日本学术振兴会;

关键词：

Clopidogrel cessation; Platelet function; VerifyNow assay;

D O I：

10.1007/s11748-015-0583-2

中图分类号：

学科分类号：

摘要：

Objective: The Japanese Circulation Society recommends discontinuation of antiplatelet therapy 7–14 days before major surgery. However, reports on the relationship between the timing of clopidogrel discontinuation and the risk of postoperative bleeding in Japanese subjects are lacking. We assessed the optimal timing of clopidogrel discontinuation before elective surgery using the VerifyNow® P2Y12 assay. In addition, the relationship between preoperative platelet function and risk of postoperative bleeding was evaluated. Methods: Study 1: Between June 2012 and December 2014, Platelet function was examined by the VerifyNow P2Y12 assay in patients scheduled for cardiac surgery, every other day after clopidogrel cessation. Study 2: We compared the preoperative platelet function, measured by the VerifyNow, with the postoperative bleeding. Results: Study 1: Twenty-four patients were included in this study. The mean P2Y12 reaction units (PRU) on Day-0 was 186, and increased significantly to 283 PRU on Day-7 in a time-dependent manner after clopidogrel discontinuation (p = 0.001). The mean PRU value significantly exceeded the cutoff of 230 on Day-5. Study 2: Correlation between the preoperative aspirin reaction units (ARU) and postoperative bleeding showed a slight inverse correlation in patients undergoing aortic valve replacement (rS = −0.363, p = 0.013), mitral valve plasty (rS = −0.300, p = 0.085) and off-pump coronary artery bypass (rS = −0.176, p = not significant). Conclusion: Platelet aggregation had already recovered at 5 days after clopidogrel cessation. Surgeons could consider decreasing the interval from clopidogrel discontinuation to surgery from the recommended 7–14 days. The VerifyNow assay can be used to predict the risk of perioperative bleeding. © 2015, The Japanese Association for Thoracic Surgery.

引用

页码：601 / 606

页数：5

共 12 条

[1] Hillis L.D., Smith P.K., Anderson J.L., Bittl J.A., Bridges C.R., Byrne J.G., Et al., 2011 ACCF/AHA guideline for coronary artery bypass graft surgery: executive summary, J Am Coll Cardiol, 58, pp. 2584-2614, (2011)
[2] Kapetanakis E.I., Medlam D.A., Boyce S.W., Haile E., Hill P.C., Dullum M.K., Et al., Clopidogrel administration prior to coronary artery bypass grafting surgery: the cardiologist’s panacea or the surgeon’s headache?, Eur Heart J, 26, pp. 576-583, (2005)
[3] Fox K.A., Mehta S.R., Peters R., Zhao F., Lakkis N., Gersh B.J., Et al., Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the clopidogrel in unstable angina to prevent recurrent ischemic events (CURE) trial, Circulation, 110, pp. 1202-1208, (2004)
[4] Leong J.Y., Baker R.A., Shah P.J., Cherian V.K., Knight J.L., Clopidogrel and bleeding after coronary artery bypass graft surgery, Ann Thorac Surg, 80, pp. 928-933, (2005)
[5] Yusuf S., Zhao F., Mehta S.R., Chrolavicius S., Tognoni G., Fox K.K., Et al., Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation, N Engl J Med, 345, pp. 494-502, (2001)
[6] Grujic D., Martin D., Perioperative clopidogrel is seven days enough?, Am Surgeon, 75, pp. 909-913, (2009)
[7] Malinin A., Pokov A., Swaim L., Kotob M., Serebruany V., Validation of a VerifyNow-P2Y12 cartridge for monitoring platelet inhibition with clopidogrel, Methods Find Exp Clin Pharmacol, 28, pp. 315-322, (2006)
[8] Breet N.J., van Werkum J.W., Bouman H.J., Kelder J.C., Ruven H.J.T., Bal E.T., Et al., Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation, JAMA J Am Med Assoc, 303, pp. 754-762, (2010)
[9] Malinin A., Pokov A., Spergling M., Defranco A., Schwartz K., Schwartz D., Et al., Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12(R) rapid analyzer: the VERIfy Thrombosis risk ASsessment (VERITAS) study, Thromb Res, 119, pp. 277-284, (2007)
[10] Paniccia R., Antonucci E., Gori A.M., Marcucci R., Giglioli C., Antoniucci D., Et al., Different methodologies for evaluating the effect of clopidogrel on platelet function in high-risk coronary artery disease patients, J Thromb Haemost, 5, pp. 1839-1847, (2007)

← 1 2 →